Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 14-16 April 2026

CVMP opinions on veterinary medicinal products

The Committee adopted a positive opinion for a marketing authorisation for Nobivac NXT HCPChFeLV, for the active immunisation of cats to reduce mortality, clinical signs and virus excretion caused by infection with feline herpesvirus type 1 (FHV); to reduce clinical signs and virus excretion caused by infection with feline calicivirus (FCV); to prevent mortality, clinical signs, leucopenia and virus excretion caused by infection with panleucopenia virus (FPL); to reduce the clinical signs and bacterial excretion caused by infection with Chlamydia felis, and to reduce persistent viraemia and clinical signs caused by feline leukaemia virus (FeLV). Nobivac NXT HCPChFeLV is the first veterinary vaccine recommended for authorisation in the EU that contains self-amplifying RNA packaged in a replication‑deficient replicon viral particle as an active substance.

The Committee adopted a positive opinion for a variation for Solensia to implement the outcome of the MAH's signal management process to update the product information by adding ‘Ataxia’, ‘Polyuria’ and ‘Polydipsia’ as very rare adverse events.

The Committee adopted a positive opinion for a variation for Startvac to allow the current vaccination schedule to be administered independently of the parturition date and administration of booster doses every three months.

Re-examinations of marketing authorisations in exceptional circumstances

The Committee adopted an opinion on the re-examination of Vectormune HVT-AIV, an avian influenza vaccine. The Committee recommended the extension for one year of the validity of the marketing authorisation in exceptional circumstances.

Maximum residue limits

The Committee adopted a report recommending inclusion of recombinant equine chorionic gonadotropin in Table 1 of the Annex to Commission Regulation (EU) 37/2010 with a “No MRL required” classification, pursuant to Section I.7 of Annex I of Commission Regulation (EU) 2018/782.

Union referrals and related procedures

The Committee concluded the referral procedure for veterinary medicinal products containing albendazole as a single active substance presented as an oral suspension for sheep. The matter was referred to the Committee by Germany under Article 82 of Regulation (EU) 2019/6 due to concerns that authorised doses or lower dose limits of 3.75-5 mg albendazole per kg bodyweight may no longer be adequate to ensure the effective use of these veterinary medicines against gastrointestinal nematodes in sheep, potentially contributing to the further development of antiparasitic resistance. The Committee adopted by consensus an opinion recommending changes to the dose and the inclusion of warnings on the effective use in the product information of these veterinary medicinal products. The Committee concluded that the benefit-risk balance of veterinary medicinal products containing albendazole as a single active substance presented as an oral suspension for sheep remains favourable and that those marketing authorisations should be amended.

Scientific advice

The Committee adopted two scientific advice reports for two biological products for dogs and pigs (one each).

Pharmacovigilance

The Committee adopted the outcomes of the signal management process for the current month. The signals submitted by marketing authorisation holders are listed, in chronological order, in the IRIS public portal: List of signals from Veterinary Signal Management. In order to access the list, the following filter should be applied in the ‘Submission type’ category: ‘Signal management submission’.

Concept papers, guidelines

Antimicrobials

The Committee adopted the revised reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in animals in the European Union: development of resistance and impact on public and animal health (EMA/CVMP/AWP/741087/2009-Rev.1) for a 4-month period of public consultation.

Quality

The Committee adopted the overview of comments on the guideline on the development and manufacture of synthetic peptides (EMA/CHMP/CVMP/QWP/367182/2025) which was published on the Agency’s website in December 2025. The guideline will come into effect on 1 June 2026.

The Committee adopted the revision of the Annex to VICH GL18 on residual solvents (EMEA/CVMP/511/03) for a 1.5-month period of public consultation.

The Committee adopted an update to the question and answer on reduced testing, which will be published on the Agency’s website under ‘Quality of medicines: questions and answers – Part 2’.

Biosimilarity

The Committee adopted a concept paper on the development of guidance on demonstration of biosimilarity of biological veterinary medicinal products (EMA/CVMP/121133/2025) for a 3-month period of public consultation.

Legislation

Further to:

the Committee’s previous advice under Article 107(6) of Regulation (EU) 2019/6 relating to antimicrobials that can be used in accordance with Articles 112, 113 and 114, and
the Committee’s previous advice under Article 114(3) relating to substances that may be used in aquatic species in accordance with Article 114(1), and
a recent request from the European Commission concerning the use of nine antimicrobial substances in accordance with Article 114(1),

the Committee adopted further guidance for transmission to the European Commission.

Additionally, further to its previous advice under Article 115(5) of Regulation (EU) 2019/6 relating to substances essential for the treatment of equine species and following a request from the European Commission for guidance concerning five substances not included in Commission Implementing Regulation (EU) 2025/901, the Committee adopted further guidance for transmission to the European Commission.

More information about the above-mentioned medicines (including their full indications), guidelines, reflection papers, questions and answers and other documents, such as overviews on comments received during consultation, can be found below in “Related content”.